Newly developed renin and prorenin assays and the clinical evaluation of renin inhibitors

Journal of Hypertension

Volumn 26, Issue 5, 2008, Pages 928-937

  Schalekamp, Maarten A D H ^a   Derkx, Frans H M ^a   Deinum, Jaap ^b   Danser, A H Jan ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Prorenin activation; Prorenin assay; Renin assay; Renin inhibitor

Indexed keywords

ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; PRORENIN; RENIN; RENIN INHIBITOR;

ADRENAL GLAND; ARTICLE; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART; HUMAN; HYPERTENSION; KIDNEY PARENCHYMA; METHODOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DETERMINATION; RADIOIMMUNOASSAY; RECEPTOR OCCUPANCY;

EID: 42049108426     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3282f6a671     Document Type: Article

References (43)

1. Sealey JE. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37:1811-1819.
2. Millar JA, Leckie BJ, Morton JJ, Jordan J, Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta 1980; 101:5-15.
3. Derkx FHM, Steunkel C, Schalekamp MPA, Visser W, Huisveld IH, Schalekamp MADH. Immunoreactive renin, prorenin, and enzymatically active renin in plasma during pregnancy and in women taking oral contraceptives. J Clin Endocrinol Metab 1986; 63:1008-1015.
4. Skinner SL. Improved assay methods for renin "concentration" and "activity" in human plasma. Methods using selective denaturation of renin substrate. Circ Res 1967; 20:391-402.
5. Derkx FHM, Schalekamp MPA, Schalekamp MADH. Two-step proreninrenin conversion. Isolation of an intermediary form of activated prorenin. J Biol Chem 1987; 262:2472-2477.
6. Lumbers ER. Activation of renin in human amniotic fluid by low pH. Enzymologia 1971; 40:329-336.
7. Leckie BJ, McGhee NK. Reversible activation-inactivation of renin in human plasma. Nature 1980; 288:702-705.
8. Derkx FHM, de Bruin RJA, van Gool JM, van den Hoek MJ, Beerendonk CC, Rosmalen F, et al. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42:1051-1063.
9. Deinum J, Derkx FHM, Schalekamp MADH. Probing epitopes on human prorenin during its proteolytic and nonproteolytic activation. Biochim Biophys Acta 1998; 1388:386-396.
10. Deinum J, Derkx FHM, Schalekamp MADH. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45:847-854.
11. Admiraal PJJ, Derkx FHM, Danser AHJ, Pieterman H, Schalekamp MADH. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension 1990; 15:44-55.
12. Admiraal PJJ, Danser AHJ, Jong MS, Pieterman H, Derkx FHM, Schalekamp MADH. Regional angiotensin II production in essential hypertension and renal artery stenosis. Hypertension 1993; 21:173-184.
13. Danser AHJ, Koning MMG, Admiraal PJJ, Sassen LMA, Derkx FHM, Verdouw PD, et al. Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol 1992; 263:H429-H437.
14. van Kats JP, de Lannoy LM, Danser AHJ, van Meegen JR, Verdouw PD, Schalekamp MADH. Angiotensin II type 1 (AT1) receptor-mediated accumulation of angiotensin II in tissues and its intracellular half-life in vivo. Hypertension 1997; 30:42-49.
15. van Kats JP, Schalekamp MADH, Verdouw PD, Duncker DJ, Danser AHJ. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 2001; 60:2311-2317.
16. van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000; 102:1556-1563.
17. van Kats JP, Chai W, Duncker DJ, Schalekamp MADH, Danser AHJ. Adrenal angiotensin. Origin and site of generation. Am J Hypertens 2005; 18:1045-1051.
18. van Kats JP, Danser AHJ, van Meegen JR, Sassen LM, Verdouw PD, Schalekamp MADH. Angiotensin production by the heart: a quantitative study in pigs with the use of radiolabeled angiotensin infusions. Circulation 1998; 98:73-81.
19. Schuijt MP, van Kats JP, de Zeeuw S, Duncker DJ, Verdouw PD, Schalekamp MADH, et al. Cardiac interstitial fluid levels of angiotensin I and II in the pig. J Hypertens 1999; 17:1885-1891.
20. Schalekamp MADH, Danser AHJ. Angiotensin II production and distribution in the kidney: I. A kinetic model. Kidney Int 2006; 69:1543-1552.
21. Schalekamp MADH, Danser AHJ. Angiotensin II production and distribution in the kidney: II: Model-based analysis of experimental data. Kidney Int 2006; 69:1553-1557.
22. Schalekamp MADH. A local prereceptor mechanism of hormone stimulus amplification: focus on angiotensin II in resistance blood vessels. J Hypertens 2006; 24:1787-1796.
23. Derkx FHM, Schalekamp MADH. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10:1213-1225.
24. Franken AAM, Derkx FHM, Man in 't Veld AJ, Hop WC, van Rens GH, Peperkamp E, et al. High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 1990; 71:1008-1015.
25. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312:1412-1417.
26. Deinum J, Ronn B, Mathiesen E, Derkx FHM, Hop WC, Schalekamp MADH. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999; 42:1006-1010.
27. Derkx FHM, Bouma BN, Schalekamp MPA, Schalekamp MADH. An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system. Nature 1979; 280:315-316.
28. Sealey JE, Atlas SA, Laragh JH, Silverberg M, Kaplan AP. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein. Proc Natl Acad Sci U S A 1979; 76:5914-5918.
29. Derkx FHM, Bouma BN, Schalekamp MADH. Prorenin-renin conversion by the contact activation system in human plasma: role of plasma protease inhibitors. J Lab Clin Med 1984; 103:560-573.
30. Osmond DH, Cooper RM. Cryoactivation and tryptic activation of blood 'prorenin' in normal man and animals. Can J Physiol Pharmacol 1978; 56:792-805.
31. Pitarresi TM, Rubattu S, Heinrikson R, Sealey JE. Reversible cryoactivation of recombinant human prorenin. J Biol Chem 1992; 267:11753-11759.
32. Sielecki AR, Hayakawa K, Fujinaga M, Murphy ME, Fraser M, Muir AK, et al. Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5 A resolution. Science 1989; 243:1346-1351.
33. Shiratori Y, Nakagawa S, Hori H, Murakami K, Umeyama H. Protein modeling of human prorenin using the molecular dynamics method. J Mol Graph 1990; 8:163-167.
34. Galen FX, Devaux C, Atlas S, Guyenne T, Menard J, Corvol P, et al. New monoclonal antibodies directed against human renin. Powerful tools for the investigation of the renin system. J Clin Invest 1984; 74:723-735.
35. Derkx FHM, Deinum J, Lipovski M, Verhaar M, Fischli W, Schalekamp MADH. Nonproteolytic "activation" of prorenin by active site-directed renin inhibitors as demonstrated by renin-specific monoclonal antibody. J Biol Chem 1992; 267:22837-22842.
36. Suzuki F, Hayakawa M, Nakagawa T, Nasir UM, Ebihara A, Iwasawa A, et al. Human prorenin has "gate and handle" regions for its nonproteolytic activation. J Biol Chem 2003; 278:22217-22222.
37. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109:1417-1427.
38. Derkx FHM, van den Meiracker AH, Fischli W, Admiraal PJJ, Man in't Veld AJ, van Brummelen P, et al. Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensins I and II in hypertensive subjects. An assay-related artefact. Am J Hypertens 1991; 4:602-609.
39. Ménard J, Guyene TT, Peyrard S, Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006; 24:529-534.
40. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20:587-597.
41. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114:1128-1135.
42. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47:894-900.
43. Cumin F, Evin G, Fehrentz JA, Seyer R, Castro B, Ménard J, et al. Inhibition of human renin by synthetic peptides derived from its prosegment. J Biol Chem 1985; 260:9154-9157.